Abstract
Due to increased global use, acute exposures to pyrethroid insecticides in humans are of clinical concern. Pyrethroids have a primary mode of action that involves interference with the inactivation of Na+ currents (INa) in excitable cells, which may include cardiac myocytes. To investigate the possible cardiac toxicity of these agents, we have examined the effects of a type-1 pyrethroid, tefluthrin, on isolated rat ventricular myocytes. Under whole-cell current-clamp, tefluthrin prolonged the mean action potential duration at 90% repolarization (APD90) by 216 ± 34% in 19 myocytes isolated from 14 hearts. About one-third of this prolongation was apparently due to persistent INa, with the balance associated with spontaneous cytosolic Ca2+ waves, and Na+-Ca2+ exchange. In some action potentials, tefluthrin also activated early after-depolarizations (EADs). Using a selected EAD-containing action potential clamp, we observed that EADs could evoke a Cd2+-sensitive membrane current (IEAD) that triggered secondary sarcoplasmic reticulum (SR) Ca2+ release. The notion that EADs could stimulate Ca2+ current was strengthened by the persistence of IEAD in myocytes exposed to extracellular Li+ and Sr2+ ions, used to minimize Na+-Ca2+ exchange and SR Ca2+ release, respectively. Tefluthrin inhibited IEAD by approximately 10%. Together, our results support an arrhythmogenic model whereby tefluthrin exposure stimulated Na+ influx, provoking cellular Ca2+ overload by reverse Na+-Ca2+ exchange. During Ca2+ waves, forward Na+-Ca2+ exchange prolonged the action potential markedly and kindled EADs by permitting the reactivation of Ca2+ current. Similar mechanisms may be involved in pyrethroid toxicity in vivo, and also in type 3 long QT syndrome, wherein Na+ channel mutations prolong INa.
Footnotes
-
This work was funded by American Heart Association Mid-Atlantic Affiliate Beginning Grant-in-aid Award 0465502U (to C.I.S.) and by National Institutes of Health Awards HL-071835 and HL-63813 (to J.S.K.S.).
-
doi:10.1124/jpet.105.084822.
-
ABBREVIATIONS: APD, action potential duration; EAD, early after-depolarization; LQT3, type 3 long QT syndrome; [Ca2+]i, intracellular calcium concentration; AP, action potential; APD90, action potential duration measured at 90% of repolarization; SR, sarcoplasmic reticulum.
-
↵1 Current address: CV Therapeutics, Inc., Palo Alto, CA.
- Received February 11, 2005.
- Accepted June 20, 2005.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|